Indications for: TRIFERIC AVNU
Iron replacement to maintain hemoglobin in adults with hemodialysis-dependent chronic kidney disease (HDD-CKD).
Limitations of Use:
Not for use in patients receiving peritoneal dialysis. Not studied in patients receiving home hemodialysis.
Administer as a slow continuous IV infusion over 3–4hrs via pre- or post-dialyzer infusion line, or a separate connection to the venous blood line. Give 6.75mg (undiluted) at each dialysis procedure.
TRIFERIC AVNU Warnings/Precautions:
Monitor for hypersensitivity reactions during and after hemodialysis until clinically stable. Have personnel and resuscitative equipment immediately available. Determine iron status on pre-dialysis blood samples. Pregnancy. Advise females of reproductive potential to use effective contraception during and for at least 2weeks after therapy completion. Nursing mothers.
TRIFERIC AVNU Classification:
Headache, peripheral edema, asthenia, AV fistula thrombosis, urinary tract infection, AV fistula site hemorrhage, pyrexia, fatigue, procedural hypotension, muscle spasms, pain in extremity, back pain, dyspnea.
Generic Drug Availability:
Ampules (5mL)—5, 40; (50mL)—4, 24; Single-dose ampules (4.5mL)—10, 40; Packets— 1, 100